Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes
    • The Product Book

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
    • Content Hubs
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2026 / March / Shining a Light into the ADC Conjugation Black Box
Pharma and Biopharma Liquid Chromatography News and Research

Shining a Light into the ADC Conjugation Black Box

A multi-year hunt for a “Goldilocks salt” paved the way for HIC-MS coupling and real-time ADC reaction monitoring

By James Strachan 03/05/2026 6 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Thought Leaders

Share

Clinical Scorecard: Shining a Light into the ADC Conjugation Black Box

At a Glance

CategoryDetail
ConditionAntibody-Drug Conjugates (ADCs)
Key MechanismsHydrophobic interaction chromatography (HIC) for real-time monitoring of bioconjugation reactions.
Target PopulationPatients requiring targeted cancer therapies using ADCs.
Care SettingPharmaceutical manufacturing and analytical development.

Key Highlights

  • Ammonium tartrate enhances HIC performance for ADC characterization.
  • Real-time monitoring of drug-to-antibody ratio (DAR) and drug load distribution (DLD).
  • Rapid 10 min HIC method developed for process analytical technology (PAT).
  • Insight into dissolution rate limitations led to significant process efficiency gains.
  • Real-time analytics can transform ADC manufacturing processes.

Guideline-Based Recommendations

Diagnosis

  • Utilize HIC for characterizing ADCs and monitoring critical quality attributes.

Management

  • Implement real-time HIC-MS coupling for ongoing process monitoring.

Monitoring & Follow-up

  • Adopt PAT methods to enhance understanding of bioconjugation reactions.

Risks

  • Traditional methods may overlook critical process dynamics leading to inefficiencies.

Patient & Prescribing Data

Patients with cancers treated by ADCs.

Improved process understanding can lead to better product quality and reduced costs.

Clinical Best Practices

  • Continuous stirring of reaction mixtures to enhance dissolution rates.
  • Use of ammonium tartrate for improved HIC separation in ADC analysis.
  • Adoption of rapid analytical methods to monitor bioconjugation in real-time.

References

  • Genentech Study on HIC-MS Coupling

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.